Back to Browse Journals » Journal of Experimental Pharmacology » Volume 5

Pharmacology and rationale for imatinib in the treatment of scleroderma

Authors Moinzadeh P, Hunzelmann N, Krieg T

Published Date April 2013 Volume 2013:5 Pages 15—22

DOI http://dx.doi.org/10.2147/JEP.S26894

Received 19 August 2012, Accepted 11 December 2012, Published 5 April 2013

Pia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg

Department of Dermatology and Venerology, University of Cologne, Germany

Abstract: Systemic sclerosis (scleroderma) is a chronic, multisystem, fibrotic disease. Although the pathogenesis is not completely understood, early vascular damage leads to an inflammatory reaction and a severe fibrotic response. Therapy of systemic sclerosis is still not convincing and is mainly restricted to the management of organ complications. A wide choice of immunosuppressive and antifibrotic drugs has been used to try to modify the course of the disease, but significant breakthroughs are still lacking. Imatinib is a tyrosine kinase inhibitor known to regulate growth, proliferation, and differentiation as well as apoptosis of cells and is already widely used for several malignancies, eg, chronic myeloid leukemia and gastrointestinal stromal tumors. It has been used in preclinical as well as clinical studies to modulate the fibrotic process in patients with systemic sclerosis. This is based on its activity to interfere selectively with both the transforming growth factor-ß and platelet-derived growth factor signaling pathway. Preclinical studies in mouse models of scleroderma showed significant anti-inflammatory and antifibrotic effects; however, several clinical, proof-of-concept trials have not yet confirmed these initially promising results.

Keywords: scleroderma, systemic sclerosis, SSc, tyrosine kinase inhibitor, imatinib

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Vaishampayan UN

Core Evidence 2014, 9:69-70

Published Date: 16 May 2014

Response to vitamin D and depression in geriatric primary care patients

Muc-Wierzgoń M, Nowakowska-Zajdel E, Klakla K, Dzięgielewska-Gęsiak S, Fatyga E, Kokot T

Clinical Interventions in Aging 2013, 8:825-827

Published Date: 3 July 2013

BAK additive influence on results

Shah RD, Lemon TI, Yarrow-Jenkins A

Clinical Ophthalmology 2013, 7:1081-1082

Published Date: 6 June 2013

Targeting nanomaterials: future drugs for cancer chemotherapy

Zhang Y, Chen T

International Journal of Nanomedicine 2012, 7:5283-5286

Published Date: 10 October 2012

Corrigendum

Siebeling L, Puhan MA, Muggensturm P, Zoller M, ter Riet G

Clinical Epidemiology 2012, 4:257-258

Published Date: 5 October 2012

Writing 3D patterns of microvessels

Juodkazis S

International Journal of Nanomedicine 2012, 7:3701-3702

Published Date: 13 July 2012

Corrigendum

Sudenga SL, Royse KE, Shrestha S

Adolescent Health, Medicine and Therapeutics 2011, 2:95-96

Published Date: 15 September 2011